Chengdu University of Traditional Chinese Medicine, School of Basic Medical Sciences.
Medicine (Baltimore). 2021 Jan 8;100(1):e24081. doi: 10.1097/MD.0000000000024081.
Liver cirrhosis is a common clinical chronic progressive disease. Due to the obstruction of blood flow after cirrhosis, it leads to long-term congestion of splenic sinus, hyperplasia of fibrous tissue and proliferation of splenic myeloid cells, resulting in hepatocirrhosis and splenomegaly. At present, western medicine still uses splenectomy and interventional therapy are the main treatment, but the adverse reactions are more and the curative effect is not good. Many clinical trials have proved that Traditional Chinese medicine has a great therapeutic effect on Hepatocirrhosis with splenomegaly, which can effectively delay the development of the disease and improve the survival rate of patients. This systematic review aims to evaluate the efficacy and safety of Traditional Chinese medicine in the treatment of hepatocirrhosis with splenomegaly.
The databases of Pubmed, CENTRAL (The Cochrane Central Register of Controlled Trials), China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (WANFANG Data), Weipu Information Chinese Periodical Service Platform (VIP), and China Biomedical Literature Service System (SinoMed) will be searched online to collect randomized controlled trials related to the treatment of hepatocirrhosis with splenomegaly with Traditional Chinese medicine The time is limited from the construction of the library to November 2020. We will use the criteria provided by Cochrane 5.1.0 for quality assessment and risk assessment of the included studies, and use the Revman 5.3 and Stata 13.0 software so as to systematically review the effectiveness of Traditional Chinese medicine for hepatocirrhosis with splenomegaly.
This systematic review will evaluate the efficacy and safety of Traditional Chinese medicine for hepatocirrhosis with splenomegaly. Because all data used in this systematic review and meta-analysis have been published, this review does not require ethical approval. In addition, all data will be analyzed anonymously during the review process.
In this study, we will evaluate the efficacy of Traditional Chinese medicine in the treatment of cirrhosis with splenomegaly.
The conclusion of this study will be evidence to ensure the efficacy of Traditional Chinese medicine© in the treatment of cirrhosis with splenomegaly and provide guidance for its treatment.
INPLASY2020110121.
肝硬化是一种常见的临床慢性进行性疾病。由于肝硬化后血流受阻，导致脾窦长期充血、纤维组织增生和脾髓样细胞增殖，导致肝硬化和脾肿大。目前，西医仍采用脾切除术和介入治疗为主，但不良反应较多，疗效不佳。大量临床试验证明，中药对肝硬化伴脾肿大有很好的治疗作用，能有效延缓病情发展，提高患者生存率。本系统评价旨在评估中药治疗肝硬化伴脾肿大的疗效和安全性。
检索 Pubmed、CENTRAL（ Cochrane 中央对照试验注册库）、中国知网（CNKI）、万方数据知识服务平台（WANFANG Data）、维普信息中文期刊服务平台（VIP）和中国生物医学文献服务系统（SinoMed）数据库，收集中药治疗肝硬化伴脾肿大的随机对照试验。时间从建库至 2020 年 11 月。采用 Cochrane 5.1.0 提供的标准对纳入研究进行质量评价和风险评估，采用 Revman 5.3 和 Stata 13.0 软件进行系统评价。
本系统评价将评估中药治疗肝硬化伴脾肿大的疗效和安全性。由于本系统评价和荟萃分析中使用的所有数据均已发表，因此本综述无需伦理批准。此外，在审查过程中，所有数据将以匿名方式进行分析。
本研究将评估中药治疗肝硬化伴脾肿大的疗效。
本研究的结论将为中药治疗肝硬化伴脾肿大的疗效提供证据，并为其治疗提供指导。
INPLASY2020110121。
